Loading
Biomarkers · Journal article
American Heart Journal · August 9, 2026
Encouraging direction, but not yet definitive.
In a trial of acute MI patients with anemia, centralized troponin review identified 156 recurrent MIs (56.7% of all recurrent events) that were missed by site reporting. These centrally identified MIs were associated with increased cardiac mortality at 30 and 180 days compared to no recurrent MI, suggesting that routine troponin surveillance detects clinically important recurrent ischemia.
Secondary analysis of a multicenter randomized controlled trial. Patients with acute myocardial infarction and anemia; specific inclusion and exclusion criteria not detailed in abstract.. Intervention: Centralized troponin review for recurrent MI detection. Compared with: Site-reported MI detection and no recurrent MI. n = 3,504.
Among 3,504 patients, 275 (7.8%) had recurrent MI within 30 days; 156 (56.7%) detected by central review only Patients with centrally identified MI had increased cardiac death risk at 30 days (RR 1.9, 95% CI 1.0–3.4) versus no recurrent MI Cardiac death risk at 180 days for centrally identified MI was RR 1.7 (95% CI 1.1–2.7) versus no recurrent MI
No absolute cardiac death rates reported, only relative risks; baseline mortality risk unknown.
Routine centralized troponin surveillance in acute MI patients may identify clinically significant recurrent ischemia missed by site reporting alone. The associated increase in cardiac mortality suggests that these troponin-detected events warrant clinical recognition and intervention, though generalizability to non-anemic MI populations is unclear.
A well-designed secondary analysis of an RCT showing that centralized troponin review identifies clinically meaningful recurrent MI with prognostic significance, but limited by single-trial population and surrogate endpoint focus.
As stated by the source record.
Quoted from the source exactly as published.
Routine centralized troponin surveillance in acute MI patients may identify clinically significant recurrent ischemia missed by site reporting alone. The associated increase in cardiac mortality suggests that these troponin-detected events warrant clinical recognition and intervention, though generalizability to non-anemic MI populations is unclear.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. The utility of routine troponin testing to identify recurrent myocardial infarction (MI) after an incident MI is unclear. We assessed the incidence and prognosis of recurrent MIs identified from centralized troponin review in patients from the Myocardial Ischemia and Transfusion (MINT) trial.Methods. The MINT trial randomized patients with acute MI and anemia to a liberal vs restrictive red blood cell transfusion strategy. Suspected recurrent MIs were identified through both site-report and centralized review of troponin levels collected for 3 days following randomization. Differences in cardiac, noncardiac, and all-cause death at 30 and 180 days were compared across patients with any site-reported MI, only centrally identified MI, and no recurrent MI.Results. Among 3,504 patients, 275 (7.8%) had a recurrent MI within 30 days; 119 (43.3%) by site-report, and 156 (56.7%) by central troponin review only. Rates of cardiac and all-cause death at 30 and 180 days were highest for patients with site-reported MI, intermediate for centrally identified MI, and lowest for no recurrent MI; rates of noncardiac death did not vary. Patients with only centrally identified recurrent MI had an increased risk of cardiac death at 30 days (RR 1.9, 95% CI 1.0-3.4) and 180 days (RR 1.7, 95% CI 1.1-2.7) compared to those without recurrent MI.Conclusions. In patients with acute MI and anemia, centralized troponin review identified more than half of all recurrent MI events. Patients with centrally identified MI had a higher risk of cardiac death than those with no recurrent MI.Trial registration. ClinicalTrials.gov NCT02981407 https://clinicaltrials.gov/study/NCT02619136.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.